Furazolidone and serotonin syndrome: is there any association? by Karamanakos, Petros N
553
CLINICS 2008;64:553-4
LETTER TO THE EDITOR
Department of Neurosurgery, University Hospital of Kuopio, Finland.
Email: petros.karamanakos@kuh.fi
FuRazOLIDOnE anD sEROTOnIn synDROmE: Is 
THERE any assOcIaTIOn?
doi: 10.1590/S1807-59322008000400024
Petros N Karamanakos
The so-called “serotonin syndrome” (SS) is a potentially 
serious condition of central and peripheral serotonergic 
hyperstimulation. It is caused by the administration of single 
drugs or combinations of drugs that elevate synaptic levels 
of serotonin. It can arise following both therapeutic doses 
and overdoses, while the most serious cases are usually 
caused by an unintended synergism between a selective 
serotonin reuptake inhibitor (SSRI) and one or several 
other medications possessing serotonergic activity, such as 
monoamine oxidase (MAO) inhibitors.1 However, sometimes 
these other drugs are not known to possess serotonergic 
activity, making diagnosis more difficult.
Furazolidone is one of the synthetic antimicrobial 
nitrofurans used in the treatment of diarrhoea or enteritis 
caused by bacteria. It may also be useful in treating 
traveller’s diarrhoea, typhoid fever, cholera and salmonella 
infections. Moreover, due to its anti-H. pylori activity,2 it has 
been used in China for more than 20 years in the treatment 
of peptic ulcers. In countries such as Brazil that have a large 
population with low socioeconomic levels and high bacterial 
resistance to metronidazole, furazolidone is believed to be a 
valuable alternative for patients who need retreatment for H. 
pylori eradication.3
As early as the 1960s, furazolidone was shown to be an 
inhibitor of MAO activity.4 In support of these results, we 
recently demonstrated for the first time that furazolidone 
produces a tremendous increase in brain serotonin levels 
in Wistar rats.5 Thus, it seems that furazolidone possess 
serotonergic activity and its combination with other 
serotonergic agents could, at least in theory, result in SS. 
However, this is not widely known and there have been few 
follow-up studies, making it possible that SS associated 
with furazolidone could go unrecognised. Labelling for 
furazolidone typically warns about interactions with MAO 
inhibitors and “tranquilisers”, but not SSRIs; in addition, no 
warnings are given regarding the possibility of SS with these 
potential interacting drugs.
In conclusion, I suggest that clinicians should be aware 
of the serotonergic properties of furazolidone, which should 
be prescribed very cautiously in patients under therapy with 
SSRIs, MAO inhibitors, or other medications that have 
a high probability of inducing SS. Due to the potentially 
serious nature of this condition, it seems prudent that 
physicians always monitor patients receiving combinations 
of serotonergic drugs and be alert to the possibility of 
“serotonergic duplication”. Retrospective case studies 
should be undertaken to look for furazolidone-induced 
SS. Moreover, basic research efforts in animal models are 
needed to better clarify the interactions of furazolidone 
with other serotonergic agents. In the meantime, physicians, 
pharmacists and clinical pharmacologists should keep the 
possibility of SS in mind when faced with patients taking 
furazolidone and who present with characteristic findings; 
anyone with such cases should publish them in Medline-
referenced journals, ideally with free internet full-text access, 
so that the information can be disseminated world-wide.
554
CLINICS 2008;64:553-4Furazolidone and serotonin syndrome: is there any association?
Karamanakos PN
REFERENCES
1. Bijl D. The serotonin syndrome. Neth J Med. 2004;62:309-13.
2. Howden A, Boswell P, Tovey F. In vitro sensitivity of Campylobacter 
pyloridis to furazolidone. Lancet. 1986;2:1035.
3. Eisig JN, Silva FM, Rodriguez TN, Hashimoto CL, Barbuti RC. 
A furazolidone-based quadruple therapy for Helicobacter pylori 
retreatment in patients with peptic ulcer disease. Clinics. 2005;60: 
485-8.
4. Palm D, Magnus U, Grobecker H, Jonsson J. Inhibition of monoamine 
oxidase by bacteriostatically active nitrofuran derivatives. Naunyn 
Schmiedebergs Arch Exp Pathol Pharmakol. 1967;256:281-300.
5. Karamanakos PN, Pappas P, Boumba VA, Thomas C, Malamas M, 
Vougiouklakis T, et al. Pharmaceutical agents known to produce 
disulfiram-like reaction: effects on hepatic ethanol metabolism and 
brain monoamines. Int J Toxicol. 2007;26:423-32.
